HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prop 65 Proposal Stirs Retailers To Request Manufacturers' Guarantees

Executive Summary

California Prop 65 amendment has retailers asking manufacturers for unrealistic guarantees that no products contain any Prop 65 chemicals, says Clif Bar & Co. Chief Counsel Amy Norris. Manufacturers should develop standard response to retailers' myriad requests and develop a plan to address any issues that could arise.

You may also be interested in...



US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish

Looking look back on US wellness market developments and events in 2019, HBW Insight finds a firm that doesn’t compete in the dietary supplement sector, Amarin, made a good bit of news that affected the industry during the year. We track news across the wellness space from the past year.

Acetaminophen Under Scrutiny In California For Prop 65 Requirements

California extends deadline for data from cancer bioassays, epidemiological studies and genotoxicity tests for review of acetaminophen as a Prop 65 chemical due to carcinogenic potential. Deadline extended to May 29 in response to Consumer Healthcare Products Association request.

California May Limit Prop 65 Short-Form Warnings To Packages Short On Space

California may move to limit when Prop 65 stakeholders can use short-form warnings on products instead of longer-form warnings because firms are opting for the shorter warnings at an unexpected rate. Manufacturers may be leaning on the short-form too much for the state's taste and to the surprise of food and drug lawyers.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel